Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00720941 · OUTCOME

Mean Number of Laboratory Visits, Radiology Visits, Home Healthcare Visits, and Medical Procedures at Day 28 of Cycles 1-4

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma · Source last updated 2025-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
visits
Interval / dispersion
Standard Deviation
Time frame
Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)

What was measured

The number of non-study laboratory visits (NSLVs), non-study radiology visits (NSRVs), and home healthcare visits (HHVs) were each collected as a single question on the eCRF. The number of non-study medical or surgical procedures (MSPs) was defined as the sum of procedures performed at outpatient or physician clinics, as well as those performed during any inpatient hospitalization.

Analysis population: Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Only those participants who had NSLVs, NSRVs, HHVs, and medical procedures were analyzed.

Groups in this outcome

Pazopanib 800 mg

Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Sunitinib 50 mg

Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg429
Sunitinib 50 mg432

Reported measurements

NSLV, Cycle 1 (n=417,414)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg417
Sunitinib 50 mg414
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.31.25Not reportedNot reportedNot reported
Sunitinib 50 mg0.31.14Not reportedNot reportedNot reported
NSLV, Cycle 2 (n=345,363)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg345
Sunitinib 50 mg363
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.30.97Not reportedNot reportedNot reported
Sunitinib 50 mg0.41.35Not reportedNot reportedNot reported
NSLV, Cycle 3 (n=299,304)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg299
Sunitinib 50 mg304
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.20.67Not reportedNot reportedNot reported
Sunitinib 50 mg0.20.58Not reportedNot reportedNot reported
NSLV, Cycle 4 (n=265,254)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg265
Sunitinib 50 mg254
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.10.49Not reportedNot reportedNot reported
Sunitinib 50 mg0.10.47Not reportedNot reportedNot reported
NSRV, Cycle 1 (n=419,414)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg419
Sunitinib 50 mg414
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.10.44Not reportedNot reportedNot reported
Sunitinib 50 mg0.10.56Not reportedNot reportedNot reported
NSRV, Cycle 2 (n=348,364)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg348
Sunitinib 50 mg364
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.10.36Not reportedNot reportedNot reported
Sunitinib 50 mg0.10.88Not reportedNot reportedNot reported
NSRV, Cycle 3 (n=299,305)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg299
Sunitinib 50 mg305
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.00.28Not reportedNot reportedNot reported
Sunitinib 50 mg0.10.33Not reportedNot reportedNot reported
NSRV, Cycle 4 (n=266,255)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg266
Sunitinib 50 mg255
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.00.24Not reportedNot reportedNot reported
Sunitinib 50 mg0.10.46Not reportedNot reportedNot reported
HHV, Cycle 1 (n=418,411)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg418
Sunitinib 50 mg411
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.00.44Not reportedNot reportedNot reported
Sunitinib 50 mg0.10.77Not reportedNot reportedNot reported
HHV, Cycle 2 (n=343,363)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg343
Sunitinib 50 mg363
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.10.52Not reportedNot reportedNot reported
Sunitinib 50 mg0.10.64Not reportedNot reportedNot reported
HHV, Cycle 3 (n=298,304)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg298
Sunitinib 50 mg304
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.10.72Not reportedNot reportedNot reported
Sunitinib 50 mg0.00.37Not reportedNot reportedNot reported
HHV, Cycle 4 (n=265,254)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg265
Sunitinib 50 mg254
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.00.49Not reportedNot reportedNot reported
Sunitinib 50 mg0.11.77Not reportedNot reportedNot reported
NSP, Cycle 1 (n=417,413)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg417
Sunitinib 50 mg413
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.20.69Not reportedNot reportedNot reported
Sunitinib 50 mg0.32.52Not reportedNot reportedNot reported
NSP, Cycle 2 (n=344,363)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg344
Sunitinib 50 mg363
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.20.68Not reportedNot reportedNot reported
Sunitinib 50 mg0.21.17Not reportedNot reportedNot reported
NSP, Cycle 3 (n=298,304)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg298
Sunitinib 50 mg304
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.20.60Not reportedNot reportedNot reported
Sunitinib 50 mg0.31.98Not reportedNot reportedNot reported
NSP, Cycle 4 (n=266,254)

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg266
Sunitinib 50 mg254
Values in visits · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0.20.85Not reportedNot reportedNot reported
Sunitinib 50 mg0.31.73Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.25
        value
        0.3
      2. group Id
        OG001
        spread
        1.14
        value
        0.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        417
      2. group Id
        OG001
        value
        414
      units
      Participants
    title
    NSLV, Cycle 1 (n=417,414)
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.97
        value
        0.3
      2. group Id
        OG001
        spread
        1.35
        value
        0.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        345
      2. group Id
        OG001
        value
        363
      units
      Participants
    title
    NSLV, Cycle 2 (n=345,363)
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.67
        value
        0.2
      2. group Id
        OG001
        spread
        0.58
        value
        0.2
    denoms
    1. counts
      1. group Id
        OG000
        value
        299
      2. group Id
        OG001
        value
        304
      units
      Participants
    title
    NSLV, Cycle 3 (n=299,304)
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.49
        value
        0.1
      2. group Id
        OG001
        spread
        0.47
        value
        0.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        265
      2. group Id
        OG001
        value
        254
      units
      Participants
    title
    NSLV, Cycle 4 (n=265,254)
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.44
        value
        0.1
      2. group Id
        OG001
        spread
        0.56
        value
        0.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        419
      2. group Id
        OG001
        value
        414
      units
      Participants
    title
    NSRV, Cycle 1 (n=419,414)
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.36
        value
        0.1
      2. group Id
        OG001
        spread
        0.88
        value
        0.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        348
      2. group Id
        OG001
        value
        364
      units
      Participants
    title
    NSRV, Cycle 2 (n=348,364)
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.28
        value
        0.0
      2. group Id
        OG001
        spread
        0.33
        value
        0.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        299
      2. group Id
        OG001
        value
        305
      units
      Participants
    title
    NSRV, Cycle 3 (n=299,305)
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.24
        value
        0.0
      2. group Id
        OG001
        spread
        0.46
        value
        0.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        266
      2. group Id
        OG001
        value
        255
      units
      Participants
    title
    NSRV, Cycle 4 (n=266,255)
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.44
        value
        0.0
      2. group Id
        OG001
        spread
        0.77
        value
        0.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        418
      2. group Id
        OG001
        value
        411
      units
      Participants
    title
    HHV, Cycle 1 (n=418,411)
  10. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.52
        value
        0.1
      2. group Id
        OG001
        spread
        0.64
        value
        0.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        343
      2. group Id
        OG001
        value
        363
      units
      Participants
    title
    HHV, Cycle 2 (n=343,363)
  11. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.72
        value
        0.1
      2. group Id
        OG001
        spread
        0.37
        value
        0.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        298
      2. group Id
        OG001
        value
        304
      units
      Participants
    title
    HHV, Cycle 3 (n=298,304)
  12. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.49
        value
        0.0
      2. group Id
        OG001
        spread
        1.77
        value
        0.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        265
      2. group Id
        OG001
        value
        254
      units
      Participants
    title
    HHV, Cycle 4 (n=265,254)
denoms
  1. counts
    1. group Id
      OG000
      value
      429
    2. group Id
      OG001
      value
      432
    units
    Participants
description
The number of non-study laboratory visits (NSLVs), non-study radiology visits (NSRVs), and home healthcare visits (HHVs) were each collected as a single question on the eCRF. The number of non-study medical or surgical procedures (MSPs) was defined as the sum of procedures performed at outpatient or physician clinics, as well as those performed during any inpatient hospitalization.
dispersion Type
Standard Deviation
groups
  1. description
    Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
    id
    OG000
    title
    Pazopanib 800 mg
  2. description
    Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
    id
    OG001
    title
    Sunitinib 50 mg
param Type
MEAN
population Description
Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Only those participants who had NSLVs, NSRVs, HHVs, and medical procedures were analyzed.
reporting Status
POSTED
time Frame
Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)
title
Mean Number of Laboratory Visits, Radiology Visits, Home Healthcare Visits, and Medical Procedures at Day 28 of Cycles 1-4
type
SECONDARY
unit Of Measure
visits

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice